Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.42 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.42 |
| ▸ | BCHE | P06276 | 3/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5655886 | 0.75 | DRD4 (0.58) | POLBADRB2 | |
| SCHEMBL5657642 | 0.71 | L3MBTL1 (0.42) | ADRB2KMT2AMEN1 | |
| SCHEMBL7186721 | 0.68 | CARM1 (0.45) | DRD2 | |
| SCHEMBL5099023 | 0.68 | HRH3 (0.44) | DRD2ADRB2 | |
| SCHEMBL4507716 | 0.68 | HRH3 (0.59) | BCHE | |
| SCHEMBL1809532 | 0.68 | HSD11B1 (0.55) | ADRB2KMT2AMEN1 | |
| SCHEMBL5102691 | 0.67 | HRH3 (0.50) | KMT2AMEN1 | |
| SCHEMBL1807918 | 0.67 | MGLL (0.54) | ADRB2KMT2AMEN1 | |
| SCHEMBL5102255 | 0.67 | CARM1 (0.65) | — | |
| SCHEMBL5109440 | 0.66 | CCR3 (0.45) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304077-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-12-04 | — | — | US | disclosed |
| US-20040102432-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| EP-1322611-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002020484-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102432-A1 | Chemical compounds | CCL11, HRH1, HRH4 | POLB 3718/4885DRD2 1111/4885ADRB2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.